These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 17109305)

  • 1. A trial of integrated buprenorphine/naloxone and HIV clinical care.
    Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Brief versus extended counseling along with buprenorphine/naloxone for HIV-infected opioid dependent patients.
    Tetrault JM; Moore BA; Barry DT; O'Connor PG; Schottenfeld R; Fiellin DA; Fiellin LE
    J Subst Abuse Treat; 2012 Dec; 43(4):433-9. PubMed ID: 22938914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HIV clinic-based buprenorphine plus naloxone versus referral for methadone maintenance therapy for treatment of opioid use disorder in HIV clinics in Vietnam (BRAVO): an open-label, randomised, non-inferiority trial.
    Korthuis PT; King C; Cook RR; Khuyen TT; Kunkel LE; Bart G; Nguyen T; Thuy DT; Bielavitz S; Nguyen DB; Tam NTM; Giang LM
    Lancet HIV; 2021 Feb; 8(2):e67-e76. PubMed ID: 33539760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic switch to buprenorphine/naloxone from buprenorphine alone: clinical experience in an Italian addiction centre.
    Montesano F; Zaccone D; Battaglia E; Genco F; Mellace V
    Clin Drug Investig; 2010; 30 Suppl 1():13-9. PubMed ID: 20450241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study.
    Altice FL; Bruce RD; Lucas GM; Lum PJ; Korthuis PT; Flanigan TP; Cunningham CO; Sullivan LE; Vergara-Rodriguez P; Fiellin DA; Cajina A; Botsko M; Nandi V; Gourevitch MN; Finkelstein R;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S22-32. PubMed ID: 21317590
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of the switch from buprenorphine to buprenorphine/naloxone in an Italian addiction treatment centre.
    Stimolo C; Favero VD; Zecchinato G; Buson R; Cusin D; Pellachin P; Simonetto P
    Clin Drug Investig; 2010; 30 Suppl 1():27-31. PubMed ID: 20450243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial.
    Weiss RD; Potter JS; Fiellin DA; Byrne M; Connery HS; Dickinson W; Gardin J; Griffin ML; Gourevitch MN; Haller DL; Hasson AL; Huang Z; Jacobs P; Kosinski AS; Lindblad R; McCance-Katz EF; Provost SE; Selzer J; Somoza EC; Sonne SC; Ling W
    Arch Gen Psychiatry; 2011 Dec; 68(12):1238-46. PubMed ID: 22065255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Counseling plus buprenorphine-naloxone maintenance therapy for opioid dependence.
    Fiellin DA; Pantalon MV; Chawarski MC; Moore BA; Sullivan LE; O'Connor PG; Schottenfeld RS
    N Engl J Med; 2006 Jul; 355(4):365-74. PubMed ID: 16870915
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug treatment outcomes among HIV-infected opioid-dependent patients receiving buprenorphine/naloxone.
    Fiellin DA; Weiss L; Botsko M; Egan JE; Altice FL; Bazerman LB; Chaudhry A; Cunningham CO; Gourevitch MN; Lum PJ; Sullivan LE; Schottenfeld RS; O'Connor PG;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(0 1):S33-8. PubMed ID: 21317592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial.
    Tanum L; Solli KK; Latif ZE; Benth JŠ; Opheim A; Sharma-Haase K; Krajci P; Kunøe N
    JAMA Psychiatry; 2017 Dec; 74(12):1197-1205. PubMed ID: 29049469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of a sublingual buprenorphine/naloxone rapidly dissolving tablet for the treatment of adults with opioid dependence: A randomized trial.
    Webster L; Hjelmström P; Sumner M; Gunderson EW
    J Addict Dis; 2016; 35(4):325-338. PubMed ID: 27267785
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with fortnightly buprenorphine/naloxone versus buprenorphine in Italy: preliminary observational data in an office-based setting.
    Amato P
    Clin Drug Investig; 2010; 30 Suppl 1():33-9. PubMed ID: 20450244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.
    Lucas GM; Chaudhry A; Hsu J; Woodson T; Lau B; Olsen Y; Keruly JC; Fiellin DA; Finkelstein R; Barditch-Crovo P; Cook K; Moore RD
    Ann Intern Med; 2010 Jun; 152(11):704-11. PubMed ID: 20513828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial.
    Fiellin DA; Schottenfeld RS; Cutter CJ; Moore BA; Barry DT; O'Connor PG
    JAMA Intern Med; 2014 Dec; 174(12):1947-54. PubMed ID: 25330017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of buprenorphine/naloxone in opioid-dependent patients: an Italian observational study.
    Magnelli F; Biondi L; Calabria R; Fiore A; Peluso E; Vonella D; Rota AG
    Clin Drug Investig; 2010; 30 Suppl 1():21-6. PubMed ID: 20450242
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of cocaine use on outcomes in HIV-infected patients receiving buprenorphine/naloxone.
    Sullivan LE; Botsko M; Cunningham CO; O'Connor PG; Hersh D; Mitty J; Lum PJ; Schottenfeld RS; Fiellin DA;
    J Acquir Immune Defic Syndr; 2011 Mar; 56 Suppl 1(Suppl 1):S54-61. PubMed ID: 21317595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination.
    Tacke U; Uosukainen H; Kananen M; Kontra K; Pentikänen H
    J Opioid Manag; 2009; 5(6):321-9. PubMed ID: 20073406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial.
    Lofwall MR; Walsh SL; Nunes EV; Bailey GL; Sigmon SC; Kampman KM; Frost M; Tiberg F; Linden M; Sheldon B; Oosman S; Peterson S; Chen M; Kim S
    JAMA Intern Med; 2018 Jun; 178(6):764-773. PubMed ID: 29799968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.